Companies · Other Health Care

AtheroMed Inc

Menlo Park · Other Health Care

Diligence memoA one-page analyst read on AtheroMed Inc — recommendation, valuation, rhythm, risks.
$24.7M
Total raised · real
5
Rounds
0.7×
Latest step-up
Top 15%
Sector rank · raised
Series A
Latest stage · inferred · Fri Dec 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time)

AtheroMed Inc looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.73× the median modeled value of Series A Other Health Care companies in 2013–2015 (187 peers) — value vs value, same stage and era.
  • Within the normal band (73% of peer median) for its niche.
Dormant
  • Last raise 12.6 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

AtheroMed Inc is one of 5376 Other Health Care companies tracked from Menlo Park. By capital raised it ranks in the upper tier (ahead of 86% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2009-10-05 Raised $2.4M (real) Modeled valuation $58M (est)$2.4M$58MSeed2009Series A · 2011-03-21 Raised $7.5M (real) Modeled valuation $152M (est)$7.5M$152MSeries A2011Series A · 2012-03-07 Raised $4.5M (real) Modeled valuation $90M (est)$4.5M$90MSeries A2012Series A · 2013-03-29 Raised $6.0M (real) Modeled valuation $120M (est)$6.0M$120MSeries A2013Series A · 2013-12-06 Raised $4.3M (real) Modeled valuation $88M (est)$4.3M$88MSeries A2013+$7.5M+$4.5M+$6.0M+$4.3MCumulative $25M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.4M · 2009
Series A$7.5M · 2011
Series A extension$4.5M · 2012
Series A extension$6.0M · 2013
Series A extension$4.3M · 2013

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$87.7M
Base estimate est.
$5.6M
Conservative case
$477.1M
Upside case
$19.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Seed · modeled $58.5M · 2009-10-052009Series A · modeled $151.9M · 2011-03-21Series A · modeled $90.4M · 2012-03-07Series A · modeled $120.2M · 2013-03-29Series A · modeled $87.7M · 2013-12-062013
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
52%
Survival probability
28% low · 71% high
1.43×/yr
Annual markup
1.80×/yr upside case
6.0 yr
Elapsed time used
12.6 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
13 mo
Avg between rounds
$5.9M/yr
Capital velocity
16.7 yr
On record since
2009
First round
5
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 10× above median
This company$24.7M
Sector median$2.4M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.8× of median
This company$4.3M
Sector median$5.6M
Modeled value — vs sector median (estimate, all stages) 4.0× above median
This company$87.7M
Sector median$22.1M

Raised more than 86% of sector peers (real $). Modeled value above 77% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #130 of 187.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)Imagine Health, Inc. · Series A Raised $15.0M · modeled $302.7M (est)Inova Labs, Inc. · Series A Raised $32.6M · modeled $302.7M (est)Spruce Health, Inc. · Series A Raised $15.0M · modeled $302.7M (est)Cephea Valve Technologies, Inc. · Series A Raised $21.2M · modeled $296.8M (est)ClarVista Medical, Inc. · Series A Raised $14.5M · modeled $293.0M (est)Minimally Invasive Devices Inc. · Series A Raised $43.3M · modeled $284.9M (est)Osprey Medical Inc. · Series A Raised $14.0M · modeled $282.5M (est)IGeneX Group, LLC · Series A Raised $13.5M · modeled $273.4M (est)Urohsd, Llc · Series A Raised $13.2M · modeled $266.9M (est)Secure EDI Holdings, LLC · Series A Raised $28.3M · modeled $263.5M (est)Sterling Healthcare Holdings, Llc · Series A Raised $13.4M · modeled $259.1M (est)Wallick Senior Housing Holdings, LLC · Series A Raised $12.8M · modeled $259.1M (est)AtheroMed Inc (this company) Raised $24.7M · modeled $87.7M (est)AtheroMed Inc
CompanyStageRaised · realValue · estvs peer med.
Imagine Health, Inc.Series A$15.0M$302.7M2.50×
Inova Labs, Inc.Series A$32.6M$302.7M2.50×
Spruce Health, Inc.Series A$15.0M$302.7M2.50×
Cephea Valve Technologies, Inc.Series A$21.2M$296.8M2.46×
ClarVista Medical, Inc.Series A$14.5M$293.0M2.42×
Minimally Invasive Devices Inc.Series A$43.3M$284.9M2.36×
Osprey Medical Inc.Series A$14.0M$282.5M2.34×
IGeneX Group, LLCSeries A$13.5M$273.4M2.26×
Urohsd, LlcSeries A$13.2M$266.9M2.21×
Secure EDI Holdings, LLCSeries A$28.3M$263.5M2.18×
Sterling Healthcare Holdings, LlcSeries A$13.4M$259.1M2.14×
Wallick Senior Housing Holdings, LLCSeries A$12.8M$259.1M2.14×
AtheroMed Inc this companySeries A$24.7M$87.7M0.73×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.4M2009-10-05$11.8M$58.5M90%
Series A$7.5M2011-03-21$34.2M$151.9M90%
Series A$4.5M2012-03-07$20.4M$90.4M90%
Series A$6.0M2013-03-29$27.1M$120.2M90%
Series A$4.3M2013-12-06$19.8M$87.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.4M2009-10-05
    • First recorded raise — entered as Seed.
  2. Series A$7.5M2011-03-21
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round 3.2× larger than the prior — scaling up.
  3. Series A$4.5M2012-03-07
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 1.7× smaller than the prior — bridge or down round.
  4. Series A$6.0M2013-03-29
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 1.3× larger than the prior — scaling up.
  5. Series A$4.3M2013-12-06
    • Raised 8 mo later, in step with the ~14 mo sector norm.
    • Round 1.4× smaller than the prior — bridge or down round.
Intelligence
2014 ~Q4
Modeled next raise · ~13mo cadence
$4.3M
Modeled next size est.range $4.3M$7.0M
0.7×
Last step-up
$5.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Casey Tansey13 other2011-03
Casper De Clercq8 other2009-10
Tony Chou6 other2009-10
David Schulte3 other2009-10
Ken Ludlum2 other2009-10
Will McGuire1 other2011-03
Alan Kaganov2009-10
Chris Danek2009-10
John To2009-10
Michael MacKinnon2013-12
Mike MacKinnon2013-03
Registry & provenance

AtheroMed Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1384897
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Omada Health, Inc.Other Health CareSeries C$71.5M$1.1Bnetwork2 shared operators · same sector
Nanostim IncOther Health CareSeries A$48.0M$191.7Mnetwork1 shared operator · same sector · same stage
Phytel IncOther Health CareSeries A$24.5M$100.9Msame sector · same stage
Molekule Group, Inc.Other Health CareSeries A$25.0M$72.6Msame sector · same stage
LoneStar Heart, Inc.Other Health CareSeries A$25.2M$84.4Msame sector · same stage
Empirical Spine, Inc.Other Health CareSeries A$25.3M$95.7Msame sector · same stage
Epica International, Inc.Other Health CareSeries A$25.6M$83.3Msame sector · same stage
Revbio, Inc.Other Health CareSeries A$27.5M$73.8Msame sector · same stage
Frequently asked
How much funding has AtheroMed Inc raised?
AtheroMed Inc has raised approximately $24.7M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is AtheroMed Inc's estimated valuation?
Provath's modeled valuation for AtheroMed Inc is approximately $87.7M (modeled range $5.6M–$477.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is AtheroMed Inc at?
AtheroMed Inc's latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Dec 06.
What does AtheroMed Inc do and where is it based?
AtheroMed Inc operates in the Other Health Care sector, based in Menlo Park.
Explore related

See where AtheroMed Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at AtheroMed Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.